SPARK is crowdfunding for our COVID-19 therapy
Posted on November 14th, 2020
The SPARK team is spearheading development of a unique COVID-19 preventative therapy, and already a Phase I clinical trial has begun in healthy volunteers in Australia. We at SPARK Stanford and SPARK GLOBAL are developing inexpensive and safe nasal drops that can provide short term, immediate immunity against SARS-CoV-2. We are rapidly bringing this therapy forward but without additional funding, the therapy’s development will come to a grinding halt.
We are asking the community to support our mission to fight COVID-19 by contributing to our project. You can read more about the project and the therapy here and make a contribution. All donations are tax-deductible.
We’ve seen promising data from vaccines in late stage development. But while we wait for a safe, effective vaccine to become available worldwide, we need every tool at our disposal to combat the COVID-19 pandemic.
The preventative therapy contains IgY antibodies against SARS-CoV-2 that are produced in chicken egg yolks and formulated into nasal drops that can be self-administered at home or on the go, providing immediate immunity for approximately four hours.
The prophylaxis is the product of an international collaboration coordinated by SPARK GLOBAL. The therapy’s rapid development is due to an incredible team effort from a unique array of partners, including academics, biotech companies, the animal products industry, and the volunteer contributions of SPARK’s industry advisors, with no expectation of profit.
SPARK has spent over $1.2 million to develop the therapy, but we need $1 million in additional funding now to conduct testing. If you can, please visit https://sparkmed.stanford.edu/covid19/ to donate, and please share our story!